This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Methylprednisolone hemisuccinate is a water soluble corticosteroid used to treat severe allergic reactions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematological disorders, neoplastic diseases, nervous system conditions, ophthalmic diseases, renal diseases, respiratory diseases, and rheumatic disorders.

Brand Names
Solu-medrol
Generic Name
Methylprednisolone hemisuccinate
DrugBank Accession Number
DB14644
Background

A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 474.55
Monoisotopic: 474.225368055
Chemical Formula
C26H34O8
Synonyms
  • Methylprednisolone hemisuccinate
  • Methylprednisolone hydrogen succinate
  • Methylprednisolone succinate

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Methylprednisolone sodium succinate (the sodium salt of methylprednisolone hemisuccinate) has the same metabolic and anti-inflammatory actions as methylprednisolone. When given parenterally and in equimolar quantities, the two compounds are equivalent in biologic activity.

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Acarbose.
AceclofenacThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone hemisuccinate is combined with Aceclofenac.
AcemetacinThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone hemisuccinate is combined with Acemetacin.
AcenocoumarolMethylprednisolone hemisuccinate may increase the anticoagulant activities of Acenocoumarol.
AcetohexamideThe risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Acetohexamide.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Methylprednisolone hemisuccinate is combined with Acetyldigitoxin.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Methylprednisolone hemisuccinate is combined with Acetylsalicylic acid.
AlbiglutideThe risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Albiglutide.
AlclofenacThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone hemisuccinate is combined with Alclofenac.
AldesleukinThe therapeutic efficacy of Aldesleukin can be decreased when used in combination with Methylprednisolone hemisuccinate.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Methylprednisolone sodium succinateLEC9GKY20K2375-03-3FQISKWAFAHGMGT-SGJOWKDISA-M
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Methylprednisolone Sodium Succinate for InjectionPowder, for solution1 g / vialIntramuscular; IntravenousTEVA Canada Limited2000-03-01Not applicableCanada flag
Methylprednisolone Sodium Succinate for InjectionPowder, for solution5 g / vialIntramuscular; IntravenousTEVA Canada LimitedNot applicableNot applicableCanada flag
Methylprednisolone Sodium Succinate for InjectionPowder, for solution500 mg / vialIntramuscular; IntravenousTEVA Canada Limited2000-03-01Not applicableCanada flag
Methylprednisolone Sodium Succinate for InjectionPowder, for solution125 mg / vialIntramuscular; IntravenousTEVA Canada Limited2000-03-01Not applicableCanada flag
Methylprednisolone Sodium Succinate for InjectionPowder, for solution40 mg / vialIntramuscular; IntravenousTEVA Canada Limited2000-03-01Not applicableCanada flag
Solu-medrolInjection, powder, for solution1 g/8mLIntramuscular; IntravenousPharmacia & Upjohn Company LLC1959-04-02Not applicableUS flag
Solu-medrolInjection, powder, for solution40 mg/1mLIntramuscular; IntravenousHF Acquisition Co. LLC, DBA HealthFirst2018-09-02Not applicableUS flag
Solu-medrolKit; Powder, for solution500 mg / vialIntramuscular; IntravenousPfizer Canada Ulc2012-01-18Not applicableCanada flag
Solu-medrolInjection, powder, for solution125 mg/1mLIntramuscular; IntravenousA S Medication Solutions1959-04-022013-07-03US flag
Solu-medrolInjection, powder, for solution125 mg/1mLIntramuscular; IntravenousRemedy Repack2017-03-17Not applicableUS flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
A-methapredInjection, powder, lyophilized, for solution40 mg/1mLIntramuscular; IntravenousHospira, Inc.2006-10-062010-07-01US flag
A-methapredInjection, powder, for solution125 mg/2mLIntramuscular; IntravenousHospira, Inc.2009-06-222013-05-01US flag
A-methapredInjection, powder, lyophilized, for solution125 mg/2mLIntramuscular; IntravenousHospira, Inc.2006-10-062010-07-01US flag
A-methapredInjection, powder, for solution40 mg/1mLIntramuscular; IntravenousHospira, Inc.2009-07-142013-05-01US flag
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution125 mg/2mLIntramuscular; IntravenousGeneYork Pharmaceuticals Group LLC2021-04-20Not applicableUS flag
Methylprednisolone sodium succinateInjection125 mg/2mLIntramuscular; IntravenousDr. Reddy's Laboratories Inc2022-03-24Not applicableUS flag
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution500 mg/8mLIntramuscular; IntravenousBedford Pharmaceuticals2008-01-082009-11-30US flag
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution40 mg/1mLIntramuscular; IntravenousCardinal Health2004-11-302019-04-30US flag
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution1 g/16mLIntramuscular; IntravenousSagent Pharmaceuticals2017-03-15Not applicableUS flag
Methylprednisolone Sodium SuccinateInjection, powder, lyophilized, for solution125 mg/2mLIntramuscular; IntravenousFresenius Kabi USA, LLC2004-11-30Not applicableUS flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
5GMR90S4KN
CAS number
2921-57-5
InChI Key
IMBXEJJVJRTNOW-XYMSELFBSA-N
InChI
InChI=1S/C26H34O8/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31)/t14-,16-,17-,19-,23+,24-,25-,26-/m0/s1
IUPAC Name
4-{2-[(1R,3aS,3bS,5S,9aR,9bS,10S,11aS)-1,10-dihydroxy-5,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}-4-oxobutanoic acid
SMILES
[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C

References

General References
  1. FDA Approved Drug Products: Solu-Medrol (methylprednisolone sodium succinate) for injection [Link]
ChemSpider
16034
ChEBI
135765
ChEMBL
CHEMBL1201265
ZINC
ZINC000003977781
Wikipedia
Methylprednisolone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionHysterectomy / Methylprednisolone / Postoperative pain1
4CompletedPreventionPostoperative Complications1
4CompletedPreventionPostoperative Delirium (POD) / Stress, Physiological1
4CompletedTreatmentAlopecia Totalis (AT) / Alopecia Universalis (AU) / Ophiasic Alopecia1
4CompletedTreatmentAsthma1
4CompletedTreatmentDrug Interaction Potentiation1
4CompletedTreatmentMigraine1
4CompletedTreatmentRheumatoid Arthritis1
4CompletedTreatmentSepsis1
4CompletedTreatmentTransplantation, Liver1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, for solutionIntramuscular; Intravenous125 mg/2mL
Injection, powder, lyophilized, for solutionIntravenous500 mg
Injection, solutionIntramuscular; Intravenous
Injection, powder, for solutionParenteral
Injection, powder, for solution125 mg
InjectionIntramuscular; Intravenous1 g/16mL
InjectionIntramuscular; Intravenous125 mg/2mL
InjectionIntramuscular; Intravenous40 mg/1mL
InjectionIntramuscular; Intravenous500 mg/8mL
Injection, powder, for solutionIntramuscular; Intravenous
Injection, powder, for solutionIntramuscular; Intravenous1 g/1
Injection, powder, for solutionIntramuscular; Intravenous125 MG
Injection, powder, for solutionIntramuscular; Intravenous500 MG
Injection, powder, for solutionIntramuscular; Intravenous500 mg/1
Injection, powder, for solution; injection, powder, lyophilized, for solutionIntramuscular; Intravenous125 mg
Injection, powder, lyophilized, for solution
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous1 g/16mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous1 g/8mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous125 mg/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous125 mg/2mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous2 g/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous2 g/30.6mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous40 mg/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous40 mg/1mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous500 mg/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous500 mg/8mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous500 mg/4mL
Powder, for solutionIntramuscular; Intravenous1 g / vial
Powder, for solutionIntramuscular; Intravenous125 mg / vial
Powder, for solutionIntramuscular; Intravenous40 mg / vial
Powder, for solutionIntramuscular; Intravenous5 g / vial
Powder, for solutionIntramuscular; Intravenous500 mg / vial
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous
Injection, powder, for solution
Tablet
PowderIntramuscular; Intravenous1000 mg/1vial
Injection, powder, for solutionIntramuscular; Intravenous1000 MG/16ML
Injection, powder, for solutionIntramuscular; Intravenous2000 MG/32ML
Injection, powder, for solutionIntramuscular; Intravenous40 MG/ML
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous500 mg
InjectionIntramuscular; Intravenous2 g/30.6mL
Injection, powder, for solutionIntracavernous; Intramuscular40 mg/1
Injection, powder, for solutionIntramuscular; Intravenous1 g/1mL
Injection, powder, for solutionIntramuscular; Intravenous1 g/8mL
Injection, powder, for solutionIntramuscular; Intravenous125 mg/1mL
Injection, powder, for solutionIntramuscular; Intravenous2 g/30.6mL
Injection, powder, for solutionIntramuscular; Intravenous40 mg/1mL
Injection, powder, for solutionIntramuscular; Intravenous500 mg/1mL
Injection, powder, for solutionIntramuscular; Intravenous500 mg/4mL
Injection, powder, for solutionIntravenous1 g/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous125 mg/1mL
Kit; powderIntramuscular; Intravenous1 g / vial
Kit; powderIntramuscular; Intravenous125 mg / vial
Kit; powderIntramuscular; Intravenous40 mg / vial
Kit; powderIntramuscular; Intravenous500 mg / vial
Kit; powder, for solutionIntramuscular; Intravenous1 g / vial
Kit; powder, for solutionIntramuscular; Intravenous125 mg / vial
Kit; powder, for solutionIntramuscular; Intravenous40 mg / vial
Kit; powder, for solutionIntramuscular; Intravenous500 mg / vial
Powder, for solutionIntravenous125 mg/1mL
PowderIntramuscular; Intravenous125 mg/1vial
PowderIntramuscular; Intravenous40 mg/1vial
PowderIntramuscular; Intravenous500 mg/1vial
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous40 mg
Injection, powder, for solutionIntramuscular; Intravenous500 mg/8ml
PowderIntramuscular; Intravenous
InjectionIntramuscular; Intravenous
Powder, for solutionIntramuscular; Intravenous; Rectal125 mg / vial
Powder, for solutionIntramuscular; Intravenous; Rectal40 mg / vial
InjectionParenteral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0264 mg/mLALOGPS
logP2.43ALOGPS
logP1.83ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)3.66ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area138.2 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity123.09 m3·mol-1ChemAxon
Polarizability49.87 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [Article]

Drug created at September 01, 2018 21:25 / Updated at May 17, 2022 10:07